Literature DB >> 15302502

Castleman's disease of the urachus.

Udo Rudloff1, Avrum Jacobson, Nora Morgenstern, Yu Chen, Benjamin R Lee.   

Abstract

Castleman's disease (angiofollicular lymphoid hyperplasia) is a rare heterogeneous group of lymphoproliferative disorders of uncertain cause. Most cases occur as mediastinal masses, although extrathoracic involvement has been reported. Castleman's disease involving the genitourinary tract, one of the most infrequent organ systems affected, has so far only been described in pararenal and retroperitoneal locations. We describe a patient with an unusual case of unicentric Castleman's disease that was located in a urachal remnant and bore a malignant appearance. The patient initially presented with abdominal pain and underwent laparoscopic radical excision of the urachal mass. Pathologic examination revealed Castleman's disease, hyaline-vascular type, with atypical lymphoid proliferation and follicular dendritic cell dysplasia. No evidence of concomitant lymphoma or sarcoma was found. Two years after surgical removal of the tumor, no recurrence was evident. To our knowledge, this is the first case of Castleman's disease presenting as a urachal tumor.

Entities:  

Mesh:

Year:  2004        PMID: 15302502     DOI: 10.1016/j.urology.2004.04.020

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  3 in total

1.  Perivesical unicentric Castleman disease initially suspected to be metastatic prostate cancer.

Authors:  Patrick J Guthrie; John V Thomas; Deniz Peker; Baris Turkbey; Soroush Rais-Bahrami
Journal:  Urol Ann       Date:  2016 Apr-Jun

2.  Castleman Disease Presenting as Renal Hilar Mass.

Authors:  Mohammad Hadi Radfar; Hamid Pakmanesh; Peyman Torbati
Journal:  J Endourol Case Rep       Date:  2015-11-01

Review 3.  Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.

Authors:  Henning Reis; Ulrich Krafft; Christian Niedworok; Orsolya Módos; Thomas Herold; Mark Behrendt; Hikmat Al-Ahmadie; Boris Hadaschik; Peter Nyirady; Tibor Szarvas
Journal:  Dis Markers       Date:  2018-03-12       Impact factor: 3.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.